chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 55.0
Sex: F
Vaccine: TDAP
Symptoms: Diarrhoea, Nausea, Urticaria
Clinical narrative: Nausea, diarrhea and hives
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: Pharmacist reported that "we had a couple patients that received 10mcg dosage from the Dark Pink Cap and a Label with a Yellow Box; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Pharmacist reported that "we had a couple patients that received 10mcg dosage from the Dark Pink Cap and a Label with a Yellow Box) and NO ADVERSE EVENT (No adverse event) in a child patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 216K22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 10 microgram. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (Pharmacist reported that "we had a couple patients that received 10mcg dosage from the Dark Pink Cap and a Label with a Yellow Box) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Pharmacist reported that "we had a couple patients that received 10mcg dosage from the Dark Pink Cap and a Label with a Yellow Box) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Pharmacist reported that "we had a couple patients that received 10mcg dosage from the Dark Pink Cap and a Label with a Yellow Box).    No concomitant medication details was reported. No treatment medication details was reported.   This case was reported for 2 Out of 18(12 Patients-Initial dose).   This case was linked to US-MODERNATX, INC.-MOD-2023-723704 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-723704:Patient 1(Master Case)
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza like illness, Pain, Pain in extremity, Pyrexia, SARS-CoV-2 test negative
Clinical narrative: 2 to 3 days of flu like reaction; The patient had arm soreness; body aches; fever; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (2 to 3 days of flu like reaction), VACCINATION SITE PAIN (The patient had arm soreness), MYALGIA (body aches) and PYREXIA (fever) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 060B22A and 048F21A) for COVID-19 prophylaxis.     The patient had chronic mold biotoxin illness, inflammatory cascade.  The patient's past medical history included Long COVID-19. Previously administered products included for Product used for unknown indication: Pfizer vaccine (primary series). Past adverse reactions to the above products included No adverse event with Pfizer vaccine. Concurrent medical conditions included Lyme disease.   On 16-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Aug-2022, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (2 to 3 days of flu like reaction), VACCINATION SITE PAIN (The patient had arm soreness), MYALGIA (body aches) and PYREXIA (fever). At the time of the report, INFLUENZA LIKE ILLNESS (2 to 3 days of flu like reaction), VACCINATION SITE PAIN (The patient had arm soreness), MYALGIA (body aches) and PYREXIA (fever) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: Negative, Negative and Negative.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The patient used the Binex Now nasal swab home test for all 3 home tests.  No treatment medications were reported.   This case was linked to MOD-2023-723682 (Patient Link).
Age: 67.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Headache, Oropharyngeal pain, Pain in extremity, Rhinorrhoea
Clinical narrative: Patient just felt sore arm after each injection; Covid 19, sore throat, headache; Nasal discharge; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Covid 19, sore throat, headache), RHINORRHOEA (Nasal discharge) and VACCINATION SITE PAIN (Patient just felt sore arm after each injection) in a 67-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7163B) for COVID-19 prophylaxis.     Question:Describe relevant medical history/conditions, allergy, concomitant diseases and risk factor.Answer:Patient has seasonal allergies and type 2 diabetes. Patient is under a lot of medications, but she only remembered Metformin.  Concurrent medical conditions included Type 2 diabetes mellitus and Seasonal allergy. Concomitant products included METFORMIN for an unknown indication.    On 27-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 08-May-2023, the patient experienced COVID-19 (Covid 19, sore throat, headache) and RHINORRHOEA (Nasal discharge). On an unknown date, the patient experienced VACCINATION SITE PAIN (Patient just felt sore arm after each injection). At the time of the report, COVID-19 (Covid 19, sore throat, headache) and RHINORRHOEA (Nasal discharge) had not resolved and VACCINATION SITE PAIN (Patient just felt sore arm after each injection) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-May-2023, SARS-CoV-2 test: Positive.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Treatment information was not provided.   This case was linked to MOD-2023-723801 (Patient Link).
Age: 67.0
Sex: F
Vaccine: COVID19-2
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Patient just felt sore arm after each injection; Covid 19, sore throat, headache; Nasal discharge; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Covid 19, sore throat, headache), RHINORRHOEA (Nasal discharge) and VACCINATION SITE PAIN (Patient just felt sore arm after each injection) in a 67-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7163B) for COVID-19 prophylaxis.     Question:Describe relevant medical history/conditions, allergy, concomitant diseases and risk factor.Answer:Patient has seasonal allergies and type 2 diabetes. Patient is under a lot of medications, but she only remembered Metformin.  Concurrent medical conditions included Type 2 diabetes mellitus and Seasonal allergy. Concomitant products included METFORMIN for an unknown indication.    On 27-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 08-May-2023, the patient experienced COVID-19 (Covid 19, sore throat, headache) and RHINORRHOEA (Nasal discharge). On an unknown date, the patient experienced VACCINATION SITE PAIN (Patient just felt sore arm after each injection). At the time of the report, COVID-19 (Covid 19, sore throat, headache) and RHINORRHOEA (Nasal discharge) had not resolved and VACCINATION SITE PAIN (Patient just felt sore arm after each injection) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-May-2023, SARS-CoV-2 test: Positive.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Treatment information was not provided.   This case was linked to MOD-2023-723801 (Patient Link).
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Dizziness
Clinical narrative: Systemic: Dizziness / Lightheadness-Mild, Additional Details: She previously has almost fainted to vaccines a couple years ago per patient. Today after the shingrix she only got a little "peaky" or lightheaded she said and felt immediately better after I gave her some water and she drank it. She said she was totally fine then and left after about 20minutes after the appointment.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal disorder
Clinical narrative: Systemic: see below-Mild, Additional Details: daughter called and reported mom was having issues with arm vaccine was given in.  Daughter stated her mom had vaccine administered in arm that she should not have due to lymph issues.  Daughter did not state specifically what was wrong with arm other than she was having issues with it and believed it was due to covid vaccine received in 2021.  At this time I have no other information.
Age: 78.0
Sex: M
Vaccine: COVID19-2
Symptoms: Muscle spasms
Clinical narrative: Muscle spasm in  tricep periodic multiple times per day, nearly every day
Age: 52.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19-2, COVID19
Symptoms: Atrial fibrillation, Atrial flutter, Electrocardiogram abnormal
Clinical narrative: None at the time of vaccine administration or immediately thereafter. Saw Afib / flutter in ECG as part of annual physical about 12 days after 3rd COVID vaccine administration in Dec 2021. Not seen AFib or Flutter in ECGs during previous annual check ups
Age: 52.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19-2, COVID19
Symptoms: Atrial fibrillation, Atrial flutter, COVID-19, Electrocardiogram, Heart rate
Clinical narrative: None at the time of vaccine administration or immediately thereafter. Saw Afib / flutter in ECG as part of annual physical about 12 days after 3rd COVID vaccine administration in Dec 2021. Not seen AFib or Flutter in ECGs during previous annual check ups
Age: 52.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19-2, COVID19
Symptoms: Heart rate increased, SARS-CoV-2 test
Clinical narrative: None at the time of vaccine administration or immediately thereafter. Saw Afib / flutter in ECG as part of annual physical about 12 days after 3rd COVID vaccine administration in Dec 2021. Not seen AFib or Flutter in ECGs during previous annual check ups
Age: 0.33
Sex: M
Vaccine: RV1
Symptoms: Ileocaecal resection, Intestinal anastomosis, Intestinal perforation, Intussusception, Laparotomy
Clinical narrative: Patient presented to the emergency department with ileo-ileocolic intussusception with perforation of the bowel wall requiring exploratory laparotomy and ileocecectomy with primary anastamosis
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Arthralgia, Chills, Lymphadenopathy, Nausea, Pain
Clinical narrative: vaccination site pain, fever, chills, body aches, nausea, joint pain, swollen glands in neck, under armpit on the same body side as vaccination,
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Pyrexia, Vaccination site pain
Clinical narrative: vaccination site pain, fever, chills, body aches, nausea, joint pain, swollen glands in neck, under armpit on the same body side as vaccination,
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Acquired diaphragmatic eventration, Acute respiratory failure, Aortic dilatation, Arteriogram coronary abnormal, Atrial enlargement
Clinical narrative: Insidious development of cough and shortness of breath. This waxed and waned over time. He first reported at 4/14/21 visit, at which time he said it had started 2 mo prior. Initially treated as post-nasal drip w no improvement. Chest x-ray nl. No benefit from trial of bronchodilator. Referred for cardiol eval in Sep - new dx aortic ectasia.  Admitted to hospital 3/19-20/2023 adm obs for acute hypoxic respir failure - initially thought to be interstitial lung disease, but BNP quite elevated and symptoms resolved with diuresis.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Brain natriuretic peptide increased, Cardiomegaly, Carotid arteriosclerosis, Chest X-ray abnormal, Cough
Clinical narrative: Insidious development of cough and shortness of breath. This waxed and waned over time. He first reported at 4/14/21 visit, at which time he said it had started 2 mo prior. Initially treated as post-nasal drip w no improvement. Chest x-ray nl. No benefit from trial of bronchodilator. Referred for cardiol eval in Sep - new dx aortic ectasia.  Admitted to hospital 3/19-20/2023 adm obs for acute hypoxic respir failure - initially thought to be interstitial lung disease, but BNP quite elevated and symptoms resolved with diuresis.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Diuretic therapy, Dyspnoea, Echocardiogram abnormal, Ejection fraction, Electrocardiogram T wave amplitude decreased
Clinical narrative: Insidious development of cough and shortness of breath. This waxed and waned over time. He first reported at 4/14/21 visit, at which time he said it had started 2 mo prior. Initially treated as post-nasal drip w no improvement. Chest x-ray nl. No benefit from trial of bronchodilator. Referred for cardiol eval in Sep - new dx aortic ectasia.  Admitted to hospital 3/19-20/2023 adm obs for acute hypoxic respir failure - initially thought to be interstitial lung disease, but BNP quite elevated and symptoms resolved with diuresis.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Electrocardiogram abnormal, Left ventricular hypertrophy, Myocardial infarction, Scan with contrast abnormal, Stress echocardiogram normal
Clinical narrative: Insidious development of cough and shortness of breath. This waxed and waned over time. He first reported at 4/14/21 visit, at which time he said it had started 2 mo prior. Initially treated as post-nasal drip w no improvement. Chest x-ray nl. No benefit from trial of bronchodilator. Referred for cardiol eval in Sep - new dx aortic ectasia.  Admitted to hospital 3/19-20/2023 adm obs for acute hypoxic respir failure - initially thought to be interstitial lung disease, but BNP quite elevated and symptoms resolved with diuresis.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Upper-airway cough syndrome
Clinical narrative: Insidious development of cough and shortness of breath. This waxed and waned over time. He first reported at 4/14/21 visit, at which time he said it had started 2 mo prior. Initially treated as post-nasal drip w no improvement. Chest x-ray nl. No benefit from trial of bronchodilator. Referred for cardiol eval in Sep - new dx aortic ectasia.  Admitted to hospital 3/19-20/2023 adm obs for acute hypoxic respir failure - initially thought to be interstitial lung disease, but BNP quite elevated and symptoms resolved with diuresis.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Amenorrhoea, Immediate post-injection reaction
Clinical narrative: I was 52 and still had regular menstruation. My period stopped after the COVID-19 booster. It stopped immediately. While I think I was approaching menopause, it is not typically a sudden full stop.
Age: 67.0
Sex: M
Vaccine: VARZOS
Symptoms: Extra dose administered
Clinical narrative: On patient request administered vaccine believed to be his first dose but later determined he had completed the two dose series in 2021.
Age: 70.0
Sex: M
Vaccine: VARZOS
Symptoms: Arthralgia, Myalgia
Clinical narrative: Continued muscular and joint pain in left shoulder and elbow now two months after injection. It is not debilitating, but it is noticeable and ongoing.
Age: 42.0
Sex: M
Vaccine: HEP, MMR, TDAP, VARCEL
Symptoms: Loss of consciousness, Syncope
Clinical narrative: After receiving vaccines, patient asked for water. Before receiving water, patient passed out/or fainted.  EMT's called. No physical injury and vitals within normal range. Patient expressed having needle phobia.
Age: 51.0
Sex: M
Vaccine: UNK
Symptoms: Magnetic resonance imaging joint, Periarthritis, Shoulder injury related to vaccine administration
Clinical narrative: Frozen shoulder developed leading to other issues SIRVA
Age: 67.0
Sex: M
Vaccine: COVID19-2, FLU4
Symptoms: Diplopia, Headache, Loss of personal independence in daily activities, Pain
Clinical narrative: Binocular double vision (with both eyes open) began the day after the booster following more typical body aches and a headache behind left eye. Double vision made it difficult to function ? had to shut one eye to read, for example. The condition began to clear up in about two months and had completely disappeared after about three months.
Age: 25.0
Sex: F
Vaccine: HEP
Symptoms: Injection site erythema, Injection site pruritus, Injection site warmth
Clinical narrative: Employee reported on 5/14/2023 with complaints of itching at injection site, Noted warmth and redness (1.75"x2" in size) to injection site.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Arthralgia, Injection site pain, Mobility decreased, Shoulder fracture, Wrong technique in product usage process
Clinical narrative: Pt. said that the shot was given on her upper arm- shoulder area- and hurt at the time.  Then next day she had a difficulty moving her arm and had pain in her shoulder- She called the pharmacy on 5/6/23 - She called the pharmacy 5/14/23 to tell us she saw a dr on 5/9/23 and was told that she has a fracture in a bone of her shoulder.  She said the Dr told her that it was the result of the immunization shot.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: X-ray limb abnormal
Clinical narrative: Pt. said that the shot was given on her upper arm- shoulder area- and hurt at the time.  Then next day she had a difficulty moving her arm and had pain in her shoulder- She called the pharmacy on 5/6/23 - She called the pharmacy 5/14/23 to tell us she saw a dr on 5/9/23 and was told that she has a fracture in a bone of her shoulder.  She said the Dr told her that it was the result of the immunization shot.
Age: 77.0
Sex: F
Vaccine: COVID19-2
Symptoms: Acute respiratory failure, Angiogram pulmonary abnormal, Arteriosclerosis coronary artery, C-reactive protein increased, COVID-19
Clinical narrative: Patient is a 77 y.o. female patient of, MD with history of CAD, hyperlipidemia, hypothyroidism, lumbar disease who presented to Hospital with cough, found to have COVID and respiratory failure.   Acute hypoxic respiratory failure COVID-19 Virus Infection Date of onset of symptoms: 3/25/2023 Symptoms present on admission: Myalgias, congestion, cough, shortness of breath Date of covid positive test: 3/25 on home test and confirmed on admission 3/28 Vaccination status: vaccinated with updated bivalent booster Imaging: CXR unremarkable.  CTPA without PE, showed mild lower lobe bilateral opacities Oxygen requirements on admission: 2 L NC Current oxygen requirements: room air Medical therapy: treated with remdesivir and steroids while admitted, given improvement and on room air, will discharge on short course of steroids CRP 113, procal normal Consultants following: none Anticipated special isolation end date: 10 days from symptom onset   CAD Hyperlipidemia Per history, home regimen of pravastatin, aspirin CT chest shows severe coronary artery calcifications  No cardiac symptoms Continue home regimen with outpatient follow up for potential stress test   Hypothyroidism Continue home Synthroid   GERD Continue home PPI
Age: 77.0
Sex: F
Vaccine: COVID19-2
Symptoms: Chest X-ray normal, Computerised tomogram thorax abnormal, Cough, Dyspnoea, Lung opacity
Clinical narrative: Patient is a 77 y.o. female patient of, MD with history of CAD, hyperlipidemia, hypothyroidism, lumbar disease who presented to Hospital with cough, found to have COVID and respiratory failure.   Acute hypoxic respiratory failure COVID-19 Virus Infection Date of onset of symptoms: 3/25/2023 Symptoms present on admission: Myalgias, congestion, cough, shortness of breath Date of covid positive test: 3/25 on home test and confirmed on admission 3/28 Vaccination status: vaccinated with updated bivalent booster Imaging: CXR unremarkable.  CTPA without PE, showed mild lower lobe bilateral opacities Oxygen requirements on admission: 2 L NC Current oxygen requirements: room air Medical therapy: treated with remdesivir and steroids while admitted, given improvement and on room air, will discharge on short course of steroids CRP 113, procal normal Consultants following: none Anticipated special isolation end date: 10 days from symptom onset   CAD Hyperlipidemia Per history, home regimen of pravastatin, aspirin CT chest shows severe coronary artery calcifications  No cardiac symptoms Continue home regimen with outpatient follow up for potential stress test   Hypothyroidism Continue home Synthroid   GERD Continue home PPI
Age: 77.0
Sex: F
Vaccine: COVID19-2
Symptoms: Myalgia, Procalcitonin normal, Respiratory failure, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: Patient is a 77 y.o. female patient of, MD with history of CAD, hyperlipidemia, hypothyroidism, lumbar disease who presented to Hospital with cough, found to have COVID and respiratory failure.   Acute hypoxic respiratory failure COVID-19 Virus Infection Date of onset of symptoms: 3/25/2023 Symptoms present on admission: Myalgias, congestion, cough, shortness of breath Date of covid positive test: 3/25 on home test and confirmed on admission 3/28 Vaccination status: vaccinated with updated bivalent booster Imaging: CXR unremarkable.  CTPA without PE, showed mild lower lobe bilateral opacities Oxygen requirements on admission: 2 L NC Current oxygen requirements: room air Medical therapy: treated with remdesivir and steroids while admitted, given improvement and on room air, will discharge on short course of steroids CRP 113, procal normal Consultants following: none Anticipated special isolation end date: 10 days from symptom onset   CAD Hyperlipidemia Per history, home regimen of pravastatin, aspirin CT chest shows severe coronary artery calcifications  No cardiac symptoms Continue home regimen with outpatient follow up for potential stress test   Hypothyroidism Continue home Synthroid   GERD Continue home PPI
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Asthenia, Blood creatinine increased, Blood iron, Blood sodium decreased
Clinical narrative: Patient is a 72 y.o. male with a history of CKD3, panhypopituitarism, C-Diff (10/2022) who presented to Hospital 3/19/2023 with c/o weakness and confusion. (+)COVID test 3/18/23  Na 132, creatinine 1.63, WBC 13, hemoglobin 12.1 chest x-ray with prominence of interstitial markings, unremarkable CT brain without contrast. He was treated with Paxlovid and remained stable on RA. He was discharged home 3/23/23 in stable condition.   1. Acute Metabolic Encephalopathy: 2/2 COVID-19 infection, AKI, hyponatremia. CT-Head 3/19/23: chronic microvascular ischemia. Improved with supportive care. 2. COVID-19 Infection: no PNA seen on CXR. Partially Vaccinated (Moderna x3, last 2021) symptom onset 3/17/23, (+)test 3/18/23. Continued 5 days of Paxlovid on 3/23/23.   3. AKI on CKD3: Baseline Cr 1.4, Cr 1.7 on admit, improved to 1.3 by 3/20/23 with holding home ARB. ARB resumed 3/21/23 and creat stable 3/23/23. 4. HTN: Held home ARB for relative hypotension and AKI. Restarted 3/21/23.Ongoing OP monioring. 5. Panhypopituitarism: Continued home Synthroid, initially on Stress-dose steroids, resumed home hydrocortisone 10mg / 5mg / 5mg on 3/22/23 6. Type 2 diabetes: Last A1c 7.3% (2/2023). SSI while inpatient. Resumed home meds on discharge. 7. Acute Hypovolemic Hyponatremia: Baseline Na 135, Na 132 on admit, due to diarrhea.  8. Hyperlipidemia: Continued  fenofibrate, held lipitor while on Paxlovid, can resume 3/24/23. 9. Chronic Iron Deficiency Anemia: Baseline Hgb 12-13, Hgb 11.3 on admit. Iron studies 3/20/23 Iron 16, Ferritin 58, Iron Sat 5%. 2 doses of IV Iron followed by PO Iron
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Cerebral ischaemia, Chest X-ray abnormal, Computerised tomogram head abnormal, Confusional state
Clinical narrative: Patient is a 72 y.o. male with a history of CKD3, panhypopituitarism, C-Diff (10/2022) who presented to Hospital 3/19/2023 with c/o weakness and confusion. (+)COVID test 3/18/23  Na 132, creatinine 1.63, WBC 13, hemoglobin 12.1 chest x-ray with prominence of interstitial markings, unremarkable CT brain without contrast. He was treated with Paxlovid and remained stable on RA. He was discharged home 3/23/23 in stable condition.   1. Acute Metabolic Encephalopathy: 2/2 COVID-19 infection, AKI, hyponatremia. CT-Head 3/19/23: chronic microvascular ischemia. Improved with supportive care. 2. COVID-19 Infection: no PNA seen on CXR. Partially Vaccinated (Moderna x3, last 2021) symptom onset 3/17/23, (+)test 3/18/23. Continued 5 days of Paxlovid on 3/23/23.   3. AKI on CKD3: Baseline Cr 1.4, Cr 1.7 on admit, improved to 1.3 by 3/20/23 with holding home ARB. ARB resumed 3/21/23 and creat stable 3/23/23. 4. HTN: Held home ARB for relative hypotension and AKI. Restarted 3/21/23.Ongoing OP monioring. 5. Panhypopituitarism: Continued home Synthroid, initially on Stress-dose steroids, resumed home hydrocortisone 10mg / 5mg / 5mg on 3/22/23 6. Type 2 diabetes: Last A1c 7.3% (2/2023). SSI while inpatient. Resumed home meds on discharge. 7. Acute Hypovolemic Hyponatremia: Baseline Na 135, Na 132 on admit, due to diarrhea.  8. Hyperlipidemia: Continued  fenofibrate, held lipitor while on Paxlovid, can resume 3/24/23. 9. Chronic Iron Deficiency Anemia: Baseline Hgb 12-13, Hgb 11.3 on admit. Iron studies 3/20/23 Iron 16, Ferritin 58, Iron Sat 5%. 2 doses of IV Iron followed by PO Iron
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Diarrhoea, Glycosylated haemoglobin increased, Haemoglobin, Hyponatraemia, Hypotension
Clinical narrative: Patient is a 72 y.o. male with a history of CKD3, panhypopituitarism, C-Diff (10/2022) who presented to Hospital 3/19/2023 with c/o weakness and confusion. (+)COVID test 3/18/23  Na 132, creatinine 1.63, WBC 13, hemoglobin 12.1 chest x-ray with prominence of interstitial markings, unremarkable CT brain without contrast. He was treated with Paxlovid and remained stable on RA. He was discharged home 3/23/23 in stable condition.   1. Acute Metabolic Encephalopathy: 2/2 COVID-19 infection, AKI, hyponatremia. CT-Head 3/19/23: chronic microvascular ischemia. Improved with supportive care. 2. COVID-19 Infection: no PNA seen on CXR. Partially Vaccinated (Moderna x3, last 2021) symptom onset 3/17/23, (+)test 3/18/23. Continued 5 days of Paxlovid on 3/23/23.   3. AKI on CKD3: Baseline Cr 1.4, Cr 1.7 on admit, improved to 1.3 by 3/20/23 with holding home ARB. ARB resumed 3/21/23 and creat stable 3/23/23. 4. HTN: Held home ARB for relative hypotension and AKI. Restarted 3/21/23.Ongoing OP monioring. 5. Panhypopituitarism: Continued home Synthroid, initially on Stress-dose steroids, resumed home hydrocortisone 10mg / 5mg / 5mg on 3/22/23 6. Type 2 diabetes: Last A1c 7.3% (2/2023). SSI while inpatient. Resumed home meds on discharge. 7. Acute Hypovolemic Hyponatremia: Baseline Na 135, Na 132 on admit, due to diarrhea.  8. Hyperlipidemia: Continued  fenofibrate, held lipitor while on Paxlovid, can resume 3/24/23. 9. Chronic Iron Deficiency Anemia: Baseline Hgb 12-13, Hgb 11.3 on admit. Iron studies 3/20/23 Iron 16, Ferritin 58, Iron Sat 5%. 2 doses of IV Iron followed by PO Iron
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Hypovolaemia, Interstitial lung disease, Metabolic encephalopathy, SARS-CoV-2 test positive, Serum ferritin normal
Clinical narrative: Patient is a 72 y.o. male with a history of CKD3, panhypopituitarism, C-Diff (10/2022) who presented to Hospital 3/19/2023 with c/o weakness and confusion. (+)COVID test 3/18/23  Na 132, creatinine 1.63, WBC 13, hemoglobin 12.1 chest x-ray with prominence of interstitial markings, unremarkable CT brain without contrast. He was treated with Paxlovid and remained stable on RA. He was discharged home 3/23/23 in stable condition.   1. Acute Metabolic Encephalopathy: 2/2 COVID-19 infection, AKI, hyponatremia. CT-Head 3/19/23: chronic microvascular ischemia. Improved with supportive care. 2. COVID-19 Infection: no PNA seen on CXR. Partially Vaccinated (Moderna x3, last 2021) symptom onset 3/17/23, (+)test 3/18/23. Continued 5 days of Paxlovid on 3/23/23.   3. AKI on CKD3: Baseline Cr 1.4, Cr 1.7 on admit, improved to 1.3 by 3/20/23 with holding home ARB. ARB resumed 3/21/23 and creat stable 3/23/23. 4. HTN: Held home ARB for relative hypotension and AKI. Restarted 3/21/23.Ongoing OP monioring. 5. Panhypopituitarism: Continued home Synthroid, initially on Stress-dose steroids, resumed home hydrocortisone 10mg / 5mg / 5mg on 3/22/23 6. Type 2 diabetes: Last A1c 7.3% (2/2023). SSI while inpatient. Resumed home meds on discharge. 7. Acute Hypovolemic Hyponatremia: Baseline Na 135, Na 132 on admit, due to diarrhea.  8. Hyperlipidemia: Continued  fenofibrate, held lipitor while on Paxlovid, can resume 3/24/23. 9. Chronic Iron Deficiency Anemia: Baseline Hgb 12-13, Hgb 11.3 on admit. Iron studies 3/20/23 Iron 16, Ferritin 58, Iron Sat 5%. 2 doses of IV Iron followed by PO Iron
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Transferrin saturation decreased, Type 2 diabetes mellitus, White blood cell count increased
Clinical narrative: Patient is a 72 y.o. male with a history of CKD3, panhypopituitarism, C-Diff (10/2022) who presented to Hospital 3/19/2023 with c/o weakness and confusion. (+)COVID test 3/18/23  Na 132, creatinine 1.63, WBC 13, hemoglobin 12.1 chest x-ray with prominence of interstitial markings, unremarkable CT brain without contrast. He was treated with Paxlovid and remained stable on RA. He was discharged home 3/23/23 in stable condition.   1. Acute Metabolic Encephalopathy: 2/2 COVID-19 infection, AKI, hyponatremia. CT-Head 3/19/23: chronic microvascular ischemia. Improved with supportive care. 2. COVID-19 Infection: no PNA seen on CXR. Partially Vaccinated (Moderna x3, last 2021) symptom onset 3/17/23, (+)test 3/18/23. Continued 5 days of Paxlovid on 3/23/23.   3. AKI on CKD3: Baseline Cr 1.4, Cr 1.7 on admit, improved to 1.3 by 3/20/23 with holding home ARB. ARB resumed 3/21/23 and creat stable 3/23/23. 4. HTN: Held home ARB for relative hypotension and AKI. Restarted 3/21/23.Ongoing OP monioring. 5. Panhypopituitarism: Continued home Synthroid, initially on Stress-dose steroids, resumed home hydrocortisone 10mg / 5mg / 5mg on 3/22/23 6. Type 2 diabetes: Last A1c 7.3% (2/2023). SSI while inpatient. Resumed home meds on discharge. 7. Acute Hypovolemic Hyponatremia: Baseline Na 135, Na 132 on admit, due to diarrhea.  8. Hyperlipidemia: Continued  fenofibrate, held lipitor while on Paxlovid, can resume 3/24/23. 9. Chronic Iron Deficiency Anemia: Baseline Hgb 12-13, Hgb 11.3 on admit. Iron studies 3/20/23 Iron 16, Ferritin 58, Iron Sat 5%. 2 doses of IV Iron followed by PO Iron
Age: 67.0
Sex: F
Vaccine: PPV
Symptoms: Erythema, Pain, Pruritus, Swelling
Clinical narrative: Itchiness, pain, redness, and swelling
Age: 79.0
Sex: F
Vaccine: COVID19-2
Symptoms: Acute respiratory failure, Aspiration, Atrial fibrillation, COVID-19, COVID-19 pneumonia
Clinical narrative: Patient is a 80 y.o. female with a history of atrial fibrillation on Eliquis, HFpEF, CKD, COPD and recent admission to Hospital 3/14/23 - 3/20/23 for COVID pneumonia who presented to Hospital 3/23/23 due to hemoptysis and recurrent dyspnea. There she developed progressive hypoxia to 10L O2. She was given CAP coverage azithromycin/Rocephin and deteriorated to requiring continuous BiPAP prior to transfer.  She was transferred to 3/24/2023 and arrived in respiratory distress and unresponsive to stimuli with copious congealed blood suctioned from the oropharynx. Made DNR CC 3/25/2023. Patient passed away 3/26/2023.        1. Acute Hypoxic Respiratory Failure: Patient requiring HHFNC for adequate oxygenation. Progressive decompensation since presentation 3/23/23, thought previously diagnosed with COVID 3/14/23 treated with Decadron 3/14 - 3/20/23. In setting of COVID, hemoptysis, and likely aspiration. Made DNR CC 3/25/2023. Comfort meds being used. Patient passed away 3/26/2023. 2. Acute Metabolic Encephalopathy: Acute onset AMS, after patient gave a history at hospital. Currently obtunded, not protecting airway with gag only to deep suction. CT head unlikely to change management.  3. Hemoptysis: Copious blood suctioned from oropharynx on arrival after report of hemoptysis 3/23/23 that reportedly resolved. 1x PCC dose given on admit.  4. Atrial fibrillation with RVR: Noted uncontrolled rate despite Cardizem drip.  Also with frequent PVCs. To discontinue rate controlling measures given DNR CC.  5. Severe Sepsis: AMS with leukocytosis, lactic acidosis and acidemia. 6. COVID Pneumonia: Diagnosed 3/14/23 after reporting a couple weeks of cough. S/p Decadron and Remdesivir treatment. 7. Chronic HFpEF: TTE 3/15/23 low normal systolic function with EF 50%, mild MR. Hypovolemic. 8. Coagulopathy: Unknown prior last dose of Eliquis, held further. Rising INR since last result at hospital concerning for multiorgan failure. Kcentra trial. 9. Code status: DNR CC, confirmed 3/25/2023 10. DVT Prophylaxis: Not indicated
Age: 79.0
Sex: F
Vaccine: COVID19-2
Symptoms: Cardiac failure, Cardiac failure chronic, Coagulopathy, Condition aggravated, Cough
Clinical narrative: Patient is a 80 y.o. female with a history of atrial fibrillation on Eliquis, HFpEF, CKD, COPD and recent admission to Hospital 3/14/23 - 3/20/23 for COVID pneumonia who presented to Hospital 3/23/23 due to hemoptysis and recurrent dyspnea. There she developed progressive hypoxia to 10L O2. She was given CAP coverage azithromycin/Rocephin and deteriorated to requiring continuous BiPAP prior to transfer.  She was transferred to 3/24/2023 and arrived in respiratory distress and unresponsive to stimuli with copious congealed blood suctioned from the oropharynx. Made DNR CC 3/25/2023. Patient passed away 3/26/2023.        1. Acute Hypoxic Respiratory Failure: Patient requiring HHFNC for adequate oxygenation. Progressive decompensation since presentation 3/23/23, thought previously diagnosed with COVID 3/14/23 treated with Decadron 3/14 - 3/20/23. In setting of COVID, hemoptysis, and likely aspiration. Made DNR CC 3/25/2023. Comfort meds being used. Patient passed away 3/26/2023. 2. Acute Metabolic Encephalopathy: Acute onset AMS, after patient gave a history at hospital. Currently obtunded, not protecting airway with gag only to deep suction. CT head unlikely to change management.  3. Hemoptysis: Copious blood suctioned from oropharynx on arrival after report of hemoptysis 3/23/23 that reportedly resolved. 1x PCC dose given on admit.  4. Atrial fibrillation with RVR: Noted uncontrolled rate despite Cardizem drip.  Also with frequent PVCs. To discontinue rate controlling measures given DNR CC.  5. Severe Sepsis: AMS with leukocytosis, lactic acidosis and acidemia. 6. COVID Pneumonia: Diagnosed 3/14/23 after reporting a couple weeks of cough. S/p Decadron and Remdesivir treatment. 7. Chronic HFpEF: TTE 3/15/23 low normal systolic function with EF 50%, mild MR. Hypovolemic. 8. Coagulopathy: Unknown prior last dose of Eliquis, held further. Rising INR since last result at hospital concerning for multiorgan failure. Kcentra trial. 9. Code status: DNR CC, confirmed 3/25/2023 10. DVT Prophylaxis: Not indicated
Age: 79.0
Sex: F
Vaccine: COVID19-2
Symptoms: Death, Depressed level of consciousness, Dyspepsia, Dyspnoea, Echocardiogram abnormal
Clinical narrative: Patient is a 80 y.o. female with a history of atrial fibrillation on Eliquis, HFpEF, CKD, COPD and recent admission to Hospital 3/14/23 - 3/20/23 for COVID pneumonia who presented to Hospital 3/23/23 due to hemoptysis and recurrent dyspnea. There she developed progressive hypoxia to 10L O2. She was given CAP coverage azithromycin/Rocephin and deteriorated to requiring continuous BiPAP prior to transfer.  She was transferred to 3/24/2023 and arrived in respiratory distress and unresponsive to stimuli with copious congealed blood suctioned from the oropharynx. Made DNR CC 3/25/2023. Patient passed away 3/26/2023.        1. Acute Hypoxic Respiratory Failure: Patient requiring HHFNC for adequate oxygenation. Progressive decompensation since presentation 3/23/23, thought previously diagnosed with COVID 3/14/23 treated with Decadron 3/14 - 3/20/23. In setting of COVID, hemoptysis, and likely aspiration. Made DNR CC 3/25/2023. Comfort meds being used. Patient passed away 3/26/2023. 2. Acute Metabolic Encephalopathy: Acute onset AMS, after patient gave a history at hospital. Currently obtunded, not protecting airway with gag only to deep suction. CT head unlikely to change management.  3. Hemoptysis: Copious blood suctioned from oropharynx on arrival after report of hemoptysis 3/23/23 that reportedly resolved. 1x PCC dose given on admit.  4. Atrial fibrillation with RVR: Noted uncontrolled rate despite Cardizem drip.  Also with frequent PVCs. To discontinue rate controlling measures given DNR CC.  5. Severe Sepsis: AMS with leukocytosis, lactic acidosis and acidemia. 6. COVID Pneumonia: Diagnosed 3/14/23 after reporting a couple weeks of cough. S/p Decadron and Remdesivir treatment. 7. Chronic HFpEF: TTE 3/15/23 low normal systolic function with EF 50%, mild MR. Hypovolemic. 8. Coagulopathy: Unknown prior last dose of Eliquis, held further. Rising INR since last result at hospital concerning for multiorgan failure. Kcentra trial. 9. Code status: DNR CC, confirmed 3/25/2023 10. DVT Prophylaxis: Not indicated
Age: 79.0
Sex: F
Vaccine: COVID19-2
Symptoms: Ejection fraction, General physical health deterioration, Haemoptysis, Heart rate abnormal, Hypovolaemia
Clinical narrative: Patient is a 80 y.o. female with a history of atrial fibrillation on Eliquis, HFpEF, CKD, COPD and recent admission to Hospital 3/14/23 - 3/20/23 for COVID pneumonia who presented to Hospital 3/23/23 due to hemoptysis and recurrent dyspnea. There she developed progressive hypoxia to 10L O2. She was given CAP coverage azithromycin/Rocephin and deteriorated to requiring continuous BiPAP prior to transfer.  She was transferred to 3/24/2023 and arrived in respiratory distress and unresponsive to stimuli with copious congealed blood suctioned from the oropharynx. Made DNR CC 3/25/2023. Patient passed away 3/26/2023.        1. Acute Hypoxic Respiratory Failure: Patient requiring HHFNC for adequate oxygenation. Progressive decompensation since presentation 3/23/23, thought previously diagnosed with COVID 3/14/23 treated with Decadron 3/14 - 3/20/23. In setting of COVID, hemoptysis, and likely aspiration. Made DNR CC 3/25/2023. Comfort meds being used. Patient passed away 3/26/2023. 2. Acute Metabolic Encephalopathy: Acute onset AMS, after patient gave a history at hospital. Currently obtunded, not protecting airway with gag only to deep suction. CT head unlikely to change management.  3. Hemoptysis: Copious blood suctioned from oropharynx on arrival after report of hemoptysis 3/23/23 that reportedly resolved. 1x PCC dose given on admit.  4. Atrial fibrillation with RVR: Noted uncontrolled rate despite Cardizem drip.  Also with frequent PVCs. To discontinue rate controlling measures given DNR CC.  5. Severe Sepsis: AMS with leukocytosis, lactic acidosis and acidemia. 6. COVID Pneumonia: Diagnosed 3/14/23 after reporting a couple weeks of cough. S/p Decadron and Remdesivir treatment. 7. Chronic HFpEF: TTE 3/15/23 low normal systolic function with EF 50%, mild MR. Hypovolemic. 8. Coagulopathy: Unknown prior last dose of Eliquis, held further. Rising INR since last result at hospital concerning for multiorgan failure. Kcentra trial. 9. Code status: DNR CC, confirmed 3/25/2023 10. DVT Prophylaxis: Not indicated
Age: 79.0
Sex: F
Vaccine: COVID19-2
Symptoms: Hypoxia, International normalised ratio increased, Lactic acidosis, Leukocytosis, Mental status changes
Clinical narrative: Patient is a 80 y.o. female with a history of atrial fibrillation on Eliquis, HFpEF, CKD, COPD and recent admission to Hospital 3/14/23 - 3/20/23 for COVID pneumonia who presented to Hospital 3/23/23 due to hemoptysis and recurrent dyspnea. There she developed progressive hypoxia to 10L O2. She was given CAP coverage azithromycin/Rocephin and deteriorated to requiring continuous BiPAP prior to transfer.  She was transferred to 3/24/2023 and arrived in respiratory distress and unresponsive to stimuli with copious congealed blood suctioned from the oropharynx. Made DNR CC 3/25/2023. Patient passed away 3/26/2023.        1. Acute Hypoxic Respiratory Failure: Patient requiring HHFNC for adequate oxygenation. Progressive decompensation since presentation 3/23/23, thought previously diagnosed with COVID 3/14/23 treated with Decadron 3/14 - 3/20/23. In setting of COVID, hemoptysis, and likely aspiration. Made DNR CC 3/25/2023. Comfort meds being used. Patient passed away 3/26/2023. 2. Acute Metabolic Encephalopathy: Acute onset AMS, after patient gave a history at hospital. Currently obtunded, not protecting airway with gag only to deep suction. CT head unlikely to change management.  3. Hemoptysis: Copious blood suctioned from oropharynx on arrival after report of hemoptysis 3/23/23 that reportedly resolved. 1x PCC dose given on admit.  4. Atrial fibrillation with RVR: Noted uncontrolled rate despite Cardizem drip.  Also with frequent PVCs. To discontinue rate controlling measures given DNR CC.  5. Severe Sepsis: AMS with leukocytosis, lactic acidosis and acidemia. 6. COVID Pneumonia: Diagnosed 3/14/23 after reporting a couple weeks of cough. S/p Decadron and Remdesivir treatment. 7. Chronic HFpEF: TTE 3/15/23 low normal systolic function with EF 50%, mild MR. Hypovolemic. 8. Coagulopathy: Unknown prior last dose of Eliquis, held further. Rising INR since last result at hospital concerning for multiorgan failure. Kcentra trial. 9. Code status: DNR CC, confirmed 3/25/2023 10. DVT Prophylaxis: Not indicated
Age: 79.0
Sex: F
Vaccine: COVID19-2
Symptoms: Metabolic encephalopathy, Mitral valve incompetence, Oropharyngeal suctioning, Pharyngeal haemorrhage, Pneumonia
Clinical narrative: Patient is a 80 y.o. female with a history of atrial fibrillation on Eliquis, HFpEF, CKD, COPD and recent admission to Hospital 3/14/23 - 3/20/23 for COVID pneumonia who presented to Hospital 3/23/23 due to hemoptysis and recurrent dyspnea. There she developed progressive hypoxia to 10L O2. She was given CAP coverage azithromycin/Rocephin and deteriorated to requiring continuous BiPAP prior to transfer.  She was transferred to 3/24/2023 and arrived in respiratory distress and unresponsive to stimuli with copious congealed blood suctioned from the oropharynx. Made DNR CC 3/25/2023. Patient passed away 3/26/2023.        1. Acute Hypoxic Respiratory Failure: Patient requiring HHFNC for adequate oxygenation. Progressive decompensation since presentation 3/23/23, thought previously diagnosed with COVID 3/14/23 treated with Decadron 3/14 - 3/20/23. In setting of COVID, hemoptysis, and likely aspiration. Made DNR CC 3/25/2023. Comfort meds being used. Patient passed away 3/26/2023. 2. Acute Metabolic Encephalopathy: Acute onset AMS, after patient gave a history at hospital. Currently obtunded, not protecting airway with gag only to deep suction. CT head unlikely to change management.  3. Hemoptysis: Copious blood suctioned from oropharynx on arrival after report of hemoptysis 3/23/23 that reportedly resolved. 1x PCC dose given on admit.  4. Atrial fibrillation with RVR: Noted uncontrolled rate despite Cardizem drip.  Also with frequent PVCs. To discontinue rate controlling measures given DNR CC.  5. Severe Sepsis: AMS with leukocytosis, lactic acidosis and acidemia. 6. COVID Pneumonia: Diagnosed 3/14/23 after reporting a couple weeks of cough. S/p Decadron and Remdesivir treatment. 7. Chronic HFpEF: TTE 3/15/23 low normal systolic function with EF 50%, mild MR. Hypovolemic. 8. Coagulopathy: Unknown prior last dose of Eliquis, held further. Rising INR since last result at hospital concerning for multiorgan failure. Kcentra trial. 9. Code status: DNR CC, confirmed 3/25/2023 10. DVT Prophylaxis: Not indicated
Age: 79.0
Sex: F
Vaccine: COVID19-2
Symptoms: Positive airway pressure therapy, Respiratory distress, Sepsis, Unresponsive to stimuli, Ventricular extrasystoles
Clinical narrative: Patient is a 80 y.o. female with a history of atrial fibrillation on Eliquis, HFpEF, CKD, COPD and recent admission to Hospital 3/14/23 - 3/20/23 for COVID pneumonia who presented to Hospital 3/23/23 due to hemoptysis and recurrent dyspnea. There she developed progressive hypoxia to 10L O2. She was given CAP coverage azithromycin/Rocephin and deteriorated to requiring continuous BiPAP prior to transfer.  She was transferred to 3/24/2023 and arrived in respiratory distress and unresponsive to stimuli with copious congealed blood suctioned from the oropharynx. Made DNR CC 3/25/2023. Patient passed away 3/26/2023.        1. Acute Hypoxic Respiratory Failure: Patient requiring HHFNC for adequate oxygenation. Progressive decompensation since presentation 3/23/23, thought previously diagnosed with COVID 3/14/23 treated with Decadron 3/14 - 3/20/23. In setting of COVID, hemoptysis, and likely aspiration. Made DNR CC 3/25/2023. Comfort meds being used. Patient passed away 3/26/2023. 2. Acute Metabolic Encephalopathy: Acute onset AMS, after patient gave a history at hospital. Currently obtunded, not protecting airway with gag only to deep suction. CT head unlikely to change management.  3. Hemoptysis: Copious blood suctioned from oropharynx on arrival after report of hemoptysis 3/23/23 that reportedly resolved. 1x PCC dose given on admit.  4. Atrial fibrillation with RVR: Noted uncontrolled rate despite Cardizem drip.  Also with frequent PVCs. To discontinue rate controlling measures given DNR CC.  5. Severe Sepsis: AMS with leukocytosis, lactic acidosis and acidemia. 6. COVID Pneumonia: Diagnosed 3/14/23 after reporting a couple weeks of cough. S/p Decadron and Remdesivir treatment. 7. Chronic HFpEF: TTE 3/15/23 low normal systolic function with EF 50%, mild MR. Hypovolemic. 8. Coagulopathy: Unknown prior last dose of Eliquis, held further. Rising INR since last result at hospital concerning for multiorgan failure. Kcentra trial. 9. Code status: DNR CC, confirmed 3/25/2023 10. DVT Prophylaxis: Not indicated
Age: 25.0
Sex: F
Vaccine: COVID19-2
Symptoms: Syncope
Clinical narrative: After getting vaccination, patient fainted in waiting room during 15 minute post vaccination time.
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Discontinued product administered
Clinical narrative: MONOVALENT VACCINE IS NO LONGER AUTHERIZIED
Age: 41.0
Sex: F
Vaccine: PNC20
Symptoms: Cellulitis
Clinical narrative: Patient received Prevnar 20 vaccine, lot number GM9409, days later was seen in Urgent Care for cellulitis/vaccine reaction. She is the second patient seen this week with a reaction to the same vaccine and same lot.
Age: 31.0
Sex: F
Vaccine: COVID19-2
Symptoms: Bell's palsy, Chest pain, Fatigue, Migraine, Nervous system disorder
Clinical narrative: Chest pain, neurological, vision, bels palsey (heavy) fatigue, headaches migraines
Age: 31.0
Sex: F
Vaccine: COVID19-2
Symptoms: Visual impairment
Clinical narrative: Chest pain, neurological, vision, bels palsey (heavy) fatigue, headaches migraines
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Blood test normal, Peripheral swelling, Skin discolouration, Ultrasound Doppler normal
Clinical narrative: In November my right leg swelled to about 3 times the size of my left.  I went into the doctor after about the 3rd day and had blood work done along with an ultrasound.  They did not find a DVT and blood work came back fine leg eventually went to normal.  Around the same time I started getting discoloration in my feet and ankles.  I started wearing compression socks and elevating my feet at night to help with circulation now a day after my 33rd birthday I noticed the discoloration has spread up my legs and looks a purplish color with light tan around it.  I stopped eating salt when this first. began as well as switched to only drinking water and green tea.  I am a contractor so I do strenuous work also go to the gym 3-5 times a week to maintain as healthy of a lifestyle as possible. I don't understand why I am still having issues.